Kari Simonsen
Pediatric Infectious Diseases · Omaha, NENPI 1154525806
Payments from drug & device makers
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$881,786in research payments, 2019–2025
Across 121 payments — averaging $7287.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$713K
- AstraZeneca$95K
- Melinta Therapeutics, LLC$40K
- Astrazeneca UK Limited$34K
- Merck$20
How this compares
Too few pediatric infectious diseases providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Other pediatric infectious diseases in Omaha
- Shirley DelairOmaha$4K
- Herbert DaviesOmaha$354
- Kari NeemannOmaha$117
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.